DRG Epidemiology’s coverage of Alzheimer’s disease (AD) comprises epidemiological estimates of key patient populations in the pharmaceutical markets of Asia pacific region. We report both the incidence and prevalence of AD for each country and the number of drug-treatment opportunities.

DRG Epidemiology’s AD forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with AD per year?
  • How will improvements in survival change the number of people living with a diagnosis of AD?
  • Of all people with AD, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
  • Of all people diagnosed with AD, how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of AD over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods. In addition, we depict the patient flow between or within different disease states for the United States, Europe, and Japan. These patient flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following AD subpopulations:

  • Total prevalent cases of AD.
  • Total prevalent cases of AD by severity (mild, moderate, severe).
  • Total prevalent cases of AD by diagnosis status.
  • Diagnosed prevalent cases of AD by drug-treatment status.
  • Diagnosed prevalent cases of mild AD by drug-treatment status.
  • Diagnosed prevalent cases of moderate AD by drug-treatment status.
  • Diagnosed prevalent cases of severe AD by drug-treatment status.

… and many more (details available on request).

Note: Coverage may vary by country and region.

Table of contents

  • Alzheimer's Disease - Epidemiology - Asia-Pacific
    • Introduction
      • Key Findings
        • Overview
          • Total Prevalence of Alzheimer's Disease per 1,000 People Aged 65+ in 2016 and 2026
          • Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of Alzheimer's Disease over the Next Ten Years
          • Total Prevalent Cases of Alzheimer's Disease by Severity
      • Methods
        • Total Incident Cases of Alzheimer's Disease
        • Total Prevalent Cases of Alzheimer's Disease
        • Total Prevalent Cases of Alzheimer's Disease by Severity
        • Diagnosed Prevalent Cases of Alzheimer's Disease
        • Drug-Treated Prevalent Cases of Alzheimer's Disease by Severity
        • Total Prevalent Cases of Alzheimer's Disease by ApoE4 Status
        • Lifetime DALYs Gained
      • Epidemiology Data
      • Reference Materials
        • Literature Review
          • Studies Included in the Analysis of Alzheimer's Disease
          • Studies Excluded from the Analysis of Alzheimer's Disease
        • Risk/Protective Factors
          • Risk/Protective Factors for Alzheimer's Disease
        • Bibliography

      Author(s): Nishant Kumar, MPH

      Nishant is a senior epidemiologist and head of oncology within the epidemiology team at Decision Resources Group. He also covers some CNS diseases, including Alzheimer’s disease and dementia. His key interests are developing interactive patient flows, and modelling disease progression to forecast commercially relevant drug-treatable incident and prevalent populations. Nishant also spends a lot of time collaborating with clients to help answer more specific questions through custom work and consulting projects.

      His qualifications include an MSc in Public Health with specialization in epidemiology and statistics from King’s College London, and a BSc in Medical Studies from the University of Birmingham.


      Related Reports

      Alzheimer's Disease - Landscape & Forecast - Disease Landscape & Forecast

      View Details

      Alzheimer's Disease | Disease Landscape and Forecast | G7 | 2020

      The Alzheimer’s disease (AD) market comprises a handful of symptomatic options that offer modest efficacy for a limited duration, leaving wide open the opportunity for more-effective alternatives—i...

      View Details

      Alzheimer's Disease - Epidemiology - Mature Markets

      DRG Epidemiology’s coverage of Alzheimer’s disease (AD) comprises epidemiological estimates of key...

      View Details